Bruce Booth Sells 88,878 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 88,878 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was sold at an average price of $34.22, for a total value of $3,041,405.16. Following the completion of the sale, the director owned 686,567 shares in the company, valued at $23,494,322.74. This represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.35, for a total value of $5,475,561.00.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.09, for a total value of $1,796,558.65.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.37, for a total value of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total value of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $5,990.00.

Sionna Therapeutics Stock Down 8.5%

Shares of NASDAQ SION opened at $38.90 on Thursday. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $43.19. The stock’s fifty day simple moving average is $26.55 and its two-hundred day simple moving average is $19.06.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Hedge Funds Weigh In On Sionna Therapeutics

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics during the second quarter valued at $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Sionna Therapeutics during the second quarter valued at $45,000. The Manufacturers Life Insurance Company grew its stake in Sionna Therapeutics by 13.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after acquiring an additional 4,489 shares in the last quarter. Virtus Investment Advisers LLC purchased a new position in Sionna Therapeutics during the second quarter valued at $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Sionna Therapeutics during the second quarter valued at $117,000.

Wall Street Analyst Weigh In

SION has been the subject of a number of research reports. Raymond James Financial initiated coverage on Sionna Therapeutics in a research report on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 price target for the company. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Jones Trading initiated coverage on Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Royal Bank Of Canada initiated coverage on Sionna Therapeutics in a research note on Wednesday, September 3rd. They issued a “sector perform” rating and a $22.00 price target for the company. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sionna Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.